STOVER JACK E 4

What Happened Jack E. Stover, a director of Traws Pharma, was granted 33,435 stock options on March 8, 2026. The award is reported as a derivative acquisition at $0.00 (no cash paid by the insider). The filing shows this was an award/grant rather than a purchase or sale.

Key Details

• Transaction date: 2026-03-08; Filing date: 2026-03-10 (filed within the typical Form 4 window)
• Security: Stock options (derivative) — 33,435 options; reported price $0.00
• Vesting: Options vest 100% on the first anniversary of the grant (per footnote)
• Shares owned after transaction: Not disclosed in this summary filing
• Footnote: Options awarded under the Issuer's 2021 Incentive Compensation Plan, granted by the compensation committee of independent directors

Context This is a standard director compensation award (options), not an option exercise or open-market trade. The $0.00 entry reflects issuance of the option award (insider did not pay cash). Such grants are common for board compensation and do not by themselves indicate the insider is buying or selling shares immediately.